Raising M&A and R&D Funding Through Series 4 Stock Acquisition Rights
First written in FY2021-Q3. 1 of 2 entries say "Achieved", first in FY2021. Latest entry: FY2021.
The whole theme swung hardest in 2020: 1 of 10 companies on the "Worse" side.
3 other companies' latest entry also says "Achieved".
- FY2021AchievedAnnual report
「All of the fourth series of stock acquisition rights issued by the company on 6 May 2021, with an exercise price adjustment clause, had been exercised by 21 July 2021.」
All of the fourth series of stock acquisition rights, issued to raise funds for M&A and capital expenditure, had been exercised by 21 July 2021. - FY2021-Q3First statedAnnual report
「(11) Specific uses of the funds to be raised Specific use of funds ① Funds for acquiring shares or interests in A-Traction, KARDIA SRL, Pathways Medical Corporation and Rev.1 Engineering, Inc. and making them subsidiaries: 14,300 ② Capital expenditure to expand the research and development structure: 8,300 ③ Funds for future M&A and capital and business alliances: 6,268 Total: 28,868」
The company announced plans to issue the fourth series of stock acquisition rights through a third-party allotment and raise estimated net proceeds of ¥2,886.8 million. The funds will be used for the acquisition of 4 companies, including A-Traction, at ¥1,430 million, capital expenditure to expand the research and development structure at ¥830 million, and future M&A and capital and business alliances at ¥626.8 million. The exercise period is from 7 May 2021 to 7 May 2024.